Paraneoplastic Hypercalcemia Secondary to Canine Mammary Tumors by Raposo-Ferreira, Talita Mariana Morata et al.
Acta Scientiae Veterinariae, 2016. 44: 1386.
 RESEARCH ARTICLE
    Pub. 1386
ISSN 1679-9216
1
Received: 24 February 2016                                                              Accepted: 28 July 2016                                                             Published: 6 September 2016
1Department of Veterinary Clinic and Surgery, UNESP, Jaboticabal, SP, Brazil. 2Department of Surgery in Small Animals, University of Franca (UNIFRAN), 
Franca, SP. 3Department of General Pathology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, 
Brazil. 4Department of Veterinary Clinic, UNESP, Botucatu, SP. CORRESPONDENCE: R. Laufer-Amorim [renee@fmvz.unesp.br - Tel.: +55 (14) 
3811-6293]. Departamento de Clínica Veterinária, Faculdade de Medicina Veterinária e Zootecina, Universidade Estadual Paulista, Rubião Junior s/nº. 
Caixa Postal 560.  CEP 18618.000 Botucatu, SP, Brazil.
Paraneoplastic Hypercalcemia Secondary to Canine Mammary Tumors
Talita Mariana Morata Raposo-Ferreira1, Giovanna Rossi Varallo1, Sabryna Gouveia Calazans2,  
Paulo Cesar Jark1, Rosana da Cruz Lino Salvador1, Mirela Tinucci-Costa1,  
Andrigo Barboza De Nardi1, Geovanni Dantas Cassali3 & Renée Laufer-Amorim4 
ABSTRACT 
Background: Paraneoplastic syndromes are complexes symptom that occur at a distinct site from the primary tumor or 
its metastasis by the production of hormone by the tissue in which the tumor appears. Paraneoplastic hypercalcemia is 
associated with an abnormal elevation of serum calcium levels and the mainly tumor related to this syndrome in canine 
is lymphoma, anal sac apocrine gland adenocarcinoma and multiple myeloma. In mammary tumors, the most frequent 
tumor that affect female dogs, this syndrome was also observed. The aims of this study were to evaluate serum calcium 
levels in female dogs with malignant mammary tumors and correlate calcium levels with clinicopathological parameters.
Materials, Methods & Results: It was evaluated fifty-one female dogs with mammary carcinomas (simple carcinomas 
and carcinoma in mixed tumors) for serum calcium levels using colorimetric test. Clinical-histopathological data as spray 
status, pseudopregnancy, tumor size, ulceration, clinical staging, histopathological type and tumor grade were also evalu-
ated in association with serum calcium levels. All dogs were treated with unilateral mastectomy. It was observed that 18 
animals (35%) had calcium serum levels increased (>11.5 mg/dL) and 56% (10/18 cases) of these animals had serum 
calcium levels higher than 12 mg/dL. All dogs with hypercalcemia were asymptomatic, including two female dogs that 
presented the highest levels (13.43 mg/dL and 14.28 mg/dL). Hypercalcemia of malignancy was related to mammary car-
cinomas after the exclusion of other causes of hypercalcemia through laboratory tests (complete blood count and serum 
biochemistry) and abdominal ultrasound. No correlation was verified between the corrected serum calcium values with 
clinical and histopathological parameters evaluated. 
Discussion: In this study, it was observed a high incidence of paraneoplastic hypercalcemia associated with canine mam-
mary tumors (35%). In humans, this syndrome is related in up to 10% of all patients with advanced cancer and with worse 
prognosis. The most frequent clinical signs of hypercalcemia are nonspecific and can be confused with other diseases, such 
as polyuria, polydipsia, anorexia, constipation, lethargy and weakness. The treatment of this syndrome is based on tumor 
resection and when necessary other treatments can be performed with fluid containing 0.9% sodium chloride, furosemide, 
prednisolone and calcitonin. Patients with asymptomatic or mildly symptomatic hypercalcemia (calcium levels <12 mg/
dL) do not require immediate treatment. Clinical signs occur more frequently with serum calcium levels higher than 15 
mg/dL. Calcium levels higher than 18 mg/dL are considered a medical emergency and the clinical signs observed are trig-
ger seizures, cardiac arrhythmia, acute renal failure and death. Most animals of this study presented mild hypercalcemia, 
that could justify the absence of clinical signs related to this syndrome, and the treatment for this syndrome was the tumor 
removal. The high serum calcium levels did not show correlation with more aggressive tumors and poorer prognosis, condi-
tions evaluated by histological type, tumor grade and clinical stage. The evaluation of serum calcium levels is an important 
clinical test to be done in female dogs with mammary tumors, besides to be an affordable and technically simple test. 
The clinical signs related to this syndrome are nonspecific and may be confused with other diseases commonly observed 
in older dogs. The data suggest that there are no correlation between serum calcium levels with aggressiveness of canine 
mammary tumors and with other clinical features.
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INTRODUCTION
Paraneoplastic hypercalcemia or hypercalcemia 
of malignancy (HM) is a paraneoplastic syndrome as-
sociated with an abnormal elevation of serum calcium. It 
is normally associated with the secretion of parathyroid 
hormone-related protein (PTH-rP) by the neoplasm. 
Other causes of HM include the following: ectopic 
production of parathormone (PTH), extensive lytic 
bone metastases, primary hyperparathyroidism, tumor-
associated prostaglandins (PGE1/2), interleukin-1beta, 
transforming growth factor-beta and receptor activator 
of nuclear factor kappa beta ligand [2,10,16,20,23,24].
Neoplasia is the most common cause of hy-
percalcemia in dogs [2,5]. Lymphoma, mainly cranial 
mediastinum, is the major tumor that causes HM, fol-
lowed by anal sac apocrine gland adenocarcinoma and 
multiple myeloma [2,8,16].
Other tumors associated with HM in dogs 
was thyroid carcinoma, bone tumors, thymoma, 
squamous cell carcinoma, melanoma, primary lung 
tumors, chronic lymphocytic leukemia, renal angio-
myxoma, parathyroid gland and mammary carcinomas 
[2,8,11,12,14,16,18,19]. 
The aims of this study were to evaluate serum 
calcium levels in female dogs with mammary carcino-
mas and its association with clinical and histopatho-
logical parameters. 
MATERIALS AND METHODS
Animals
Fifty-one female dogs examined at the Veteri-
nary Oncology Service of FCAV/UNESP, Jaboticabal, 
SP, Brazil with mammary carcinoma had serum cal-
cium levels evaluated by colorimetric test. The mean 
age of the animals was 10.24 ± 2.48 years. The treat-
ment of all patients consisted of unilateral mastectomy. 
Clinical-histopathological data as spray status, 
pseudopregnancy, tumor size, ulceration, clinical stag-
ing, histopathological type and tumor grade were evalu-
ated in association with serum calcium levels. Clinical 
staging was obtained by the evaluation of tumor size, 
nodal status and metastasis according to a modified 
WHO clinical staging system, stage I (T1N0M0), 
stage II (T2N0M0), stage III (T3N0M0), stage IV 
(TanyN1M0), and stage V (TanyNanyM1) [21]. The 
animals received 3-dimensional thoracic radiographs 
and abdominal ultrasound to assess metastatic disease. 
Complete blood count and serum biochemistry 
(creatinine, urea, alanine aminotransferase and alkaline 
phosphatase) analyses results were within the normal 
range for the species. 
Histopathological analysis
For histopathological evaluations mammary 
gland tumors were fixed in 10% buffered formalin and 
then embedded in paraffin. The tissues were cut into 
5 μm thick sections and stained with hematoxylin and 
eosin (HE). All cases were reviewed and re-classified 
independently by two veterinary pathologists. The 
histological classification was performed according to 
Cassali et al. [3] and tumor grade into grade I, grade 
II and grade III [6].
Evaluation of serum calcium
The total serum calcium levels were evaluated 
by the colorimetric method (Labtest). The results were 
corrected by albumin levels according to the formula: 
Calcium - Albumin + 3.5 and the values are reported in 
mg/dL [2]. The reference value range was 8.0 to 11.5 
mg/dL [1]. The calcium measurement was performed 
before surgery. 
Data and statistical analysis
The analysis of serum calcium values and the 
association with clinical and histopathological param-
eters were performed by nonparametric Kruskal-Wallis 
or Mann-Whitney U- tests. The results were considered 
to be statistically significant at P < 0.05. GraphPad 
Prism 5 software was used for all of the statistical 
analysis (GraphPad Software Inc., La Jolla, CA). 
RESULTS
Hypercalcemia was observed in 18 animals 
(35%) with calcium serum levels higher than 11.5 
mg/dL. Moreover, 56% (10/18 cases) of the female 
dogs with hypercalcemia had serum calcium levels 
higher than 12 mg/dL (Table 1). However, all dogs 
with hypercalcemia were asymptomatic. Other causes 
of hypercalcemia were excluded by laboratory tests 
(complete blood count and serum biochemistry) and 
abdominal ultrasound. 
The frequency of histopathological types is 
represented in Table 2. According to the tumor grade, 
74% of cases were grade I, 20% were grade II and 6% 
were grade III. No correlation was verified between 
the corrected serum calcium value with clinical and 
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histopathological parameters (Figures 1 and 2, re-
spectively, P > 0.05). The tumors were divided into 
simple carcinomas and carcinomas in mixed tumor 
to histopathological analysis. Serum calcium mean 
values associated with clinicopathological features are 
presented in Table 3.
Figure 1. Corrected calcium serum level analysis according to clinical parameters. A)- Reproductive status. B)- Pseudopregnancy. C)- Tumor size. D)- 
Tumor stage. [The bars indicate the median value].
Figure 2. Evaluation of calcium serum levels with histopathological features. A)- Histopathological types. B)- Tumor grade. [The bars indicate the 
median value. Ca = carcinoma].
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Table 1. Clinical parameters and total serum calcium values from female dogs with mammary tumors.
Patient
Reproductive 
status
Pseudopregnancy Contraceptive use
Tumor 
stage
Ca* 
(mg/dL)
1 Intact Yes No III 9.06
2 Intact No No IV 10.07
3 Intact Yes No III 12.16
4 Intact Yes No II 12.60
5 Intact No No I 10.53
6 Intact ** ** I 11.48
7 Intact No No I 8.60
8 Neutered Yes No I 9.98
9 Intact Yes No IV 8.40
10 Neutered No No III 10.31
11 Intact No No II 8.12
12 Intact No No I 11.46
13 Intact No No I 9.42
14 Intact No No I 10.94
15 Intact No No II 9.95
16 Intact Yes No I 9.57
17 Intact Yes No II 11.52
18 Intact No No I 10.66
19 Intact No No III 10.63
20 Intact No No III 10.13
21 Intact No Yes I 12.21
22 Intact No No IV 12.19
23 Intact Yes No III 11.77
24 Intact ** ** I 11.10
25 Intact No No I 11.36
26 Intact No No I 8.8
27 Neutered No No I 9.42
28 Neutered No No I 11.99
29 Neutered No No II 11.64
30 Neutered No No I 9.16
31 Intact Yes No III 10.06
32 Intact No No I 11.67
33 Intact Yes Yes I 13.43
34 Intact Yes No III 14.28
35 Intact Yes No V 11.15
36 Neutered No No II 12.75
37 Intact No No III 11.93
38 Neutered No No II 10.96
39 Intact Yes No III 8.50
40 Intact ** ** IV 11.91
41 Intact No No II 11.14
42 Intact ** ** II 12.15
43 Intact ** ** I 12.28
44 Intact Yes No V 11.05
45 Neutered ** ** I 11.76
46 Neutered No No I 12.63
47 Neutered Yes No I 10.91
48 Neutered Yes No II 11.04
49 Intact ** ** I 11.26
50 Intact ** ** I 11.37
51 Intact ** ** V 10.92
*Calcium serum levels corrected by albumin. **Information not provided by the owner.
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Table 2. Histopathological diagnosis from mammary gland tumors (n = 51).
Histopathological type Frequency
Anaplastic carcinoma 1 (2%)
Micropapillary carcinoma 1 (2%)
Carcinoma in situ 2 (4%)
Papillary carcinoma 2 (4%)
Solid carcinoma 4 (8%)
Carcinoma in mixed tumor 17 (33%)
Tubular carcinoma 24 (47%)
Table 3. Mean value of corrected serum calcium associated with histopathological and clinical parameters.
Variable Corrected serum calcium mean values (mg/dL) 
Histopathological type
Carcinoma in mixed tumor 11.12 ± 1.150
Simple carcinoma 10.85 ± 1.438
Tumor grade
I 11.02 ± 1.396
II 10.86 ± 1.06790
III 11.03 ± 1.60
Tumor Size
< 3 cm 11 ± 1.436
3 to 5 cm 11.08 ± 1.399
> 5 cm 10.77 ± 1.159
Tumor Stage
I 10.97 ± 1.261
II 11.08 ± 1.399
III 10.88 ± 1.690
IV 10.64 ± 1.766
V 11.04 ± 0.1153
Reproductive State
Intact 10.90 ± 1.433
Neutered 10.05 ± 1.171
Pseudopregnancy
Absence 10.77 ± 1.279
DISCUSSION
The evaluation of serum calcium levels in 
this study showed a high incidence of this syndrome 
associated with canine mammary tumors (35%). The 
hypercalcemia was correlated with a paraneoplastic 
syndrome after the exclusion of other diseases. 
In humans, paraneoplastic hypercalcemia oc-
curs in up to 10% of all patients with advanced cancer 
and is commonly associated with worse prognosis 
[7,15]. This syndrome was associated with high PTR-
rP secretion by breast cancer in women [22]. Positive 
immunohistochemistry expression of PTH-rP was 
present in 60% of 102 women with breast tumors, 
however, serum calcium levels were not increased in 
these cases [22]. 
The most common clinical signs of hypercal-
cemia are nonspecific such as polyuria, polydipsia, 
anorexia, constipation, lethargy, and weakness [2,16]. 
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The polyuria caused by hypercalcemia occurs through 
reduced anti diuretic hormone (ADH) function because 
of calcium excess. The excess of calcium decreases 
water reabsorption in the renal tubules and induces 
compensatory polydipsia [4].
Patients with asymptomatic or mildly symp-
tomatic hypercalcemia (calcium levels <12 mg/dL) do 
not require immediate treatment [9]. Clinical signs are 
usually observed with serum calcium levels higher than 
15 mg/dL [2]. However, calcium serum values higher 
than 18 mg/dL may trigger seizures, cardiac arrhyth-
mia, acute renal failure and death, being considered a 
medical emergency [2,16]. Most animals of this study 
presented mild hypercalcemia and that could justify the 
absence of clinical signs, however the two female dogs 
with the highest serum calcium levels (13.43 mg/dL 
and 14.28 mg/dL) were also asymptomatic.
The main treatment of HM consists of tumor 
resection [2,16]. Other treatments can be performed 
with fluid containing 0.9% sodium chloride, furo-
semide administration in hydrated patients or pred-
nisolone and calcitonin treatment depending on the 
patient’s condition [15,16].
The treatment of the dogs of this study was 
based only on surgical tumor removal by unilateral 
mastectomy. The surgery is also the main treatment 
choice for mammary tumors [3,21].
Hypercalcemia of malignancy was described in 
a female dog, Teckel, with complex mammary carci-
noma. The animal presented 13.9 mg/dL of serum cal-
cium levels and although normal parathyroid hormone 
concentration, PTH-related protein concentration was 
markedly increased. The dog also presented as clinical 
signs slight lethargy, polyuria and polydipsia and the 
treatment of HM was based on surgical removal [1]. 
PTHrP expression was evaluated by immuno-
histochemistry in eight canine mammary tumors (be-
nign and malignant mixed tumors) and in four animals 
was observed HM, however in two normocalcemic 
dogs this protein was present, although the numbers of 
immunoreactive cells and the immunostaining intensity 
were lower than hypercalcemic animals [13]. 
No association between serum calcium levels 
and clinical-histopathological features were observed 
in this study. Additionally, there were no correla-
tion between high serum calcium levels and more 
aggressive tumors and poorer prognosis, conditions 
evaluated by histological type, tumor grade and clini-
cal stage.
CONCLUSIONS
The evaluation of serum calcium levels is an 
important clinical test to be done in female dogs with 
mammary tumors, besides to be an affordable and 
technically simple test. The clinical signs related to 
HM are nonspecific and may be confused with other 
diseases commonly observed in older dogs. This study 
suggest that there are no correlation between serum 
calcium levels with aggressiveness of canine mammary 
tumors and with other clinical features.
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